What are the recent or latest development in gene therapy?
Results: A large variety of therapeutic genes are under investigation, such as tumour suppressor, suicide, antiangiogenesis, inflammatory cytokine and micro-RNA genes. Recent progress concerns new vectors, such as oncolytic viruses, and the synergy between viral gene therapy, chemotherapy and radiation therapy.
What are non-viral vectors for gene therapy?
The non-viral vectors are Naked DNA, particle based and chemical based. They are administered by direct administration (plasmid DNA/Naked DNA)/ chemical /physical. Most of cardiovascular clinical trials use non-viral vectors as a mode of gene transfer.
What is non-viral gene delivery?
The nonviral gene delivery methods, on the other hand, use synthetic or natural compounds or physical forces to deliver a piece of DNA into a cell. The materials used are generally less toxic and immunogenic than the viral counterparts.
What is the current status of gene therapy research?
So, there is no clinical trial on human germline gene therapy. Currently, somatic gene therapy is safe for the management of several disorders in human beings. Gene therapy effectively treats several diseases due to increased understanding of disease pathogenesis and improved gene delivery technologies.
What is the current status of the human genome project?
In 2003, an accurate and complete human genome sequence was finished and made available to scientists and researchers two years ahead of the original Human Genome Project schedule and at a cost less than the original estimated budget.
What are the types of non-viral vectors?
Non-viral vectors can be loosely grouped as plasmid DNA, liposome-DNA complexes (lipoplexes), and polymer-DNA complexes (polyplexes) (1). Oligonucleotides and their analogues, either alone or in complexes, are also an example of non-viral vector-mediated gene transfer.
What is the difference between viral vectors and non-viral vectors?
Gene delivery systems include viral vectors and non-viral vectors. Viral vectors are the most effective, but their application is limited by their immunogenicity, oncogenicity and the small size of the DNA they can transport. Non-viral vectors are safer, of low cost, more reproducible and do not present DNA size limit.
What are non-viral and viral vectors?
There are two types of vectors, viral and non-viral. Viral vectors are currently a delivery vehicle used in FDA-approved gene therapies. Non-viral techniques are currently being studied as a safe and effective way to deliver genetic material to cells for therapeutic effect.
What are the current applications of gene therapy?
Gene therapy holds promise for treating a wide range of diseases, such as cancer, cystic fibrosis, heart disease, diabetes, hemophilia and AIDS. Researchers are still studying how and when to use gene therapy. Currently, in the United States, gene therapy is available only as part of a clinical trial.
What kind of gene therapy is currently available?
Currently, one gene therapy medication, Luxturna®, has been approved by the U.S. Food and Drug Administration (FDA) for use in the United States. Luxturna treats certain inherited retinal (eye) diseases.
Are non-viral vectors the future of gene delivery?
Although non-viral vectors are low in their cytotoxicity, immunogenicity, and mutagenesis, attracting more and more researchers to explore the promising delivery system, they do not carry ideal characteristics and have faced critical challenges, including gene transfer efficiency, specificity, gene expression duration, and safety.
What was the first non-viral gene delivery technology?
In fact, the first reported non-viral gene delivery was based on calcium phosphate, back in the 1960s (54).
Should you use a viral or non-viral vector?
Using a viral vector has historically been controversial. Even though viral vectors are not known to cause any harm to patients, the small potential to trigger immunogenic responses and transgene mis-insertion risks, etc., has led many in the field to keep seeking a non-viral delivery system (4, 5).
Can the PLL dendrimer be used as a gene delivery vector?
Recent studies have expanded the choice of amino acid from lysine to arginine or other substitutions, bringing additional benefits to the PLL dendrimer as a gene delivery vector.